Leerink Partners Remains a Hold on Quanterix (QTRX)
Leerink Partners analyst Puneet Souda maintained a Hold rating on Quanterix (QTRX – Research Report) on June 2. The company's shares closed yesterday at $5.58.
Confident Investing Starts Here:
Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Bruker, and Guardant Health. According to TipRanks, Souda has an average return of -12.3% and a 29.46% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quanterix with a $12.33 average price target.
Based on Quanterix's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $30.33 million and a GAAP net loss of $20.5 million. In comparison, last year the company earned a revenue of $32.07 million and had a GAAP net loss of $10.07 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business Wire
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46 th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9 th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa ® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn.
Business Insider
2 days ago
- Business Insider
William Blair Sticks to Its Buy Rating for Rapid7 (RPD)
In a report released today, Jonathan Ho from William Blair maintained a Buy rating on Rapid7 (RPD – Research Report). The company's shares closed today at $23.17. Confident Investing Starts Here: According to TipRanks, Ho is a 4-star analyst with an average return of 11.4% and a 60.75% success rate. Ho covers the Technology sector, focusing on stocks such as Tyler Technologies, CyberArk Software, and Cloudflare. Rapid7 has an analyst consensus of Hold, with a price target consensus of $30.19. The company has a one-year high of $44.48 and a one-year low of $21.61. Currently, Rapid7 has an average volume of 944.8K. Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPD in relation to earlier this year. Most recently, in April 2025, Christina Luconi, the CPO of RPD sold 12,551.00 shares for a total of $290,102.82.
